▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
Building a Better Future For Patients with NAFLD and NASH
On International NASH Day 2023, join Michael Betel of the Fatty Liver Alliance as he addresses NAFLD and NASH, their prevalence and impact. Discover solutions including medical education, patient awareness, and advocacy. Learn about the Alliance's future goals.
View More ⏩
Link Between NAFLD and Heart Failure – A Cardiology Perspective
Join Dr Marat Fudim in this webinar as he delves into the complex interplay between non-alcoholic fatty liver disease (NAFLD) and heart failure. Uncover the paramount importance of comprehending the intersection between these two conditions in our pursuit of adequate healthcare solutions.
View More ⏩
Multistakeholder Approach to Innovations in NAFLD Care
Discover the importance of a multistakeholder approach in NAFLD care, addressing the challenges of comorbidities, patient identification, and innovative strategies to improve treatment outcomes and healthcare coordination.
View More ⏩
The Odyssey for an Optimal NASH Biomarker: Challenges and Opportunities in 2023
Explore the challenges and opportunities in the quest for a non-invasive diagnosis tool of non-alcoholic steatohepatitis (NASH) with insights from Dr Giada Sebastiani, associate professor of medicine at McGill University Health Center in Canada.
View More ⏩
NAFLD Pathophysiologic Role of Intrahepatic Vasculature
Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions that portal hypertension is present in patients with NAFLD and can be evident in the early stages which is caused by intrahepatic vascular alterations. Further, he explores the different types of drugs that will help change the course of the disease.
View More ⏩
Non-Invasive Assessment of cACLD and Portal Hypertension
Dr. Jörn Schattenberg (Germany) analyses the latest on the assessment in cirrhosis along with his own case study.
View More ⏩
Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications
Fibrosis is an independent predictor of liver-related mortality but rarely if ever occurs without NASH as NASH is the progressive form of the disease and drives fibrosis progression. This means the question arises on whether anti-fibrotic drugs are better than anti-NASH drugs and vice versa which Dr. Vlad Ratziu explores in this video.
View More ⏩
Burden of Liver-Related Comorbidities in Cardiovascular Disease
In this video Prof. Sven Francque explores that NAFLD is prevalent in patients with cardiovascular disease, but this does not prove bidirectional causality. Vascular mechanisms contribute to NASH pathogenesis and drugs used in CVD management show some benefit on NAFLD.
View More ⏩
How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and management into the care of diabetic patients in order to provide a holistic approach for the patient in order for improved patient outcomes.
View More ⏩
HCC Pathogenesis in NASH and the Impact of Fibrosis
Dr. Scott Friedman talks about HCC pathogenesis in NASH and the impact of fibrosis. This video is adapted from a lecture Dr. Scott Friedman gave at the Paris NASH meeting and illustrates the highlights of that topic in this video.
View More ⏩
Natural history & clinical outcomes in adults with NAFLD
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic fatty liver disease (NAFLD) with lessons from cohort studies and placebo arms of trials. The take home points are that the natural history of NAFLD is variable
View More ⏩
The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in the progression of chronic liver diseases. The key points addressed in this video are that co-existent fatty liver and related metabolic factors, including obesity and diabetes mellitus, exacerbate liver injury in patients with another chronic liver disease(s).
View More ⏩
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES